japan stock market


U.S. stocks are only a few points away from new all-time highs… But not every part of the U.S. market has been thriving.   Health care stocks recently fell 12% from their August highs to their pre-election lows… hitting an eight-month low in the process.   Have they bottomed? Is it time to buy? Or is this the beginning of a major downtrend?   Let's take a closer look and find out…   Health care stocks were falling before the election, when Hillary Clinton was expected to win.   The stock market expected things would stay "status quo" with Obamacare, and it didn't think that would be good for health care companies' profits.   Then, the election result surprised the markets. Trump was elected, and the sector soared.   So where do we go from here?  

japan stock market: Delta Technology Holdings Limited(DELT)


Advisors’ Opinion:

  • [By Jim Robertson]

    On Wednesday, our Under the Radar Moversnewsletter suggested going long on small capChinese chemical stock Delta Technology Holdings Ltd(NASDAQ: DELT):

japan stock market: Comp En De Mn Cemig ADS(CIG)

Advisors’ Opinion:

  • [By Lisa Levin]

    Non-cyclical consumer goods & services sector was the top gainer in the US market on Wednesday. Top gainers in the sector included Cia Energetica de Minas Gerais CEMIG-ADR (NYSE: CIG), Companhia Paranaense de Energia (ADR) (NYSE: ELP), and NRG Energy Inc (NYSE: NRG).

  • [By Lisa Levin]

    In trading on Monday, utilities shares fell 0.66 percent. Meanwhile, top losers in the sector included RGC Resources Inc. (NASDAQ: RGCO), down 5 percent, and Cia Energetica de Minas Gerais CEMIG-ADR (NYSE: CIG), down 5 percent.

  • [By Lisa Levin]

    In trading on Friday, utilities shares fell by 0.33 percent. Meanwhile, top losers in the sector included Cia Energetica de Minas Gerais CEMIG-ADR (NYSE: CIG), down 3 percent, and Companhia Paranaense de Energia (ADR) (NYSE: ELP), down 3 percent.

  • [By Lisa Levin]

    Friday afternoon, the utilities sector proved to be a source of strength for the market. Leading the sector was strength from Cia Energetica de Minas Gerais CEMIG-ADR (NYSE: CIG) and Pampa Energia S.A. (ADR) (NYSE: PAM).

japan stock market: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors’ Opinion:

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha) Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha) Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period. Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share. Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement. Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share. Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76. QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share. Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering. Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston
  • [By Johanna Bennett]

    Nothing guts a drug stock like bad clinical trial data. Shares of Ultragenyx Pharmaceutical (RARE) fell as much as 10% after a seizure medication failed in a phase II study.

    Trading at a recent $72.22, the shares were down 7.7% after earlier falling as much as 10% to $70.51

    The seizure drug UX007 was tested as a treatment for glucose transporter type-1 deficiency syndromeor Glut1 DSamong a small group of patients. Data released Wednesday showed that it only cut the rate of seizures in the drug arm by 13.4% compared to the placebo arm, falling short of statistical significance.


    Investigators, though, teased out a clinically — though not statistically — significant benefit for patients experiencing what are called absence seizures. Ultragenyx now intends to focus on that in a Phase III pivotal trial.

    Leerik analyst Joseph Schwartz called the selloff a buying opportunity.

    We had been cautious on this asset (and its two programs – G1DS and long-chain fatty acid oxidation disorder/LC-FAOD; LINK) – but believe the selling pressure after mkt. presents a buying opportunity ahead of a more de-risked X-linked hypophosphatemia (XLH) Ph.3 data in 1H17.


    Cowen analyst Eric Schmidt remained convinced of RAREs long-term prospects thanks to a diversified orphan disease pipeline. And analysts at Credit Suisse see more catalysts ahead in 2017.

    We are buyers on a pullback and we like RAREs setup for the remainder of 2017…Remaining 2017 catalysts keep us buyers on a pullback: We see Q2:17 KRN23 ph3 adult XLH data, H1:17 rhGUS FDA/EMA submission, potential KRN23 CHMP decision in mid-17 (based on late-2016 EMA submission/validation), H2:17 Ace-ER ph3 GNEM data, and potential KRN23 FDA submission in late-17/early-18 as upcoming catalysts worth owning for.

  • [By Jon C. Ogg]

    Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) was indicated down 7% at $72.85 on Thursday due to results from a seizure medication study. It was downgraded to Neutral from Overweight at Piper Jaffray, and Wedbushlowered its target for the stock.

japan stock market: Owens Realty Mortgage, Inc.(ORM)

Advisors’ Opinion:

  • [By Markus Aarnio]

    Owens Realty Mortgage (ORM) is a real estate investment trust that invests in commercial real estate mortgage loans primarily in the Western U.S. The company specializes in loans that require speed and flexibility. Owens Realty Mortgage is externally managed and advised by Owens Financial Group.

Leave a Reply

Your email address will not be published. Required fields are marked *